AKT1 and non-small cell lung carcinoma: Therefore, miR-10a could enhance the growth and metastasis of NSCLC by activating the PTEN/AKT/ERK signaling pathway, thus providing a potential molecular therapeutic target for treatment of NSCLC patients.